Supplementation of L-arginine improves hypertension and lipid metabolism but not insulin resistance in diabetic rats.
Nitric oxide (NO) plays an important role in glucose and lipid metabolism. We previously reported that NO synthesis inhibitors, such as NG-nitro-L-arginine methyl ester (L-NAME), deteriorate insulin sensitivity and lipid metabolism, while the addition of L-arginine reverses this deterioration. L-arginine is a precursor of NO, and is used as a supplement in the US. In the present study, we evaluated whether the administration of L-arginine alone improves insulin resistance and serum lipid levels in insulin-resistant and hypertriglycemic rat models. Diabetic rats were divided into 3 groups: the control (Cont) group (standard diet), the L-NAME group (diet containing L-NAME), and the Arg group (diet containing L-arginine). After 4 weeks of breeding, urinary NOx, glucose infusion rate (GIR), glucose and lipid tolerance tests were performed. Urinary NOx levels were significantly lower in the L-NAME group than in the Cont group. The GIR in the L-NAME group was significantly lower than that in the Cont group, suggesting increased insulin resistance. However, the administration of L-arginine did not influence insulin resistance in the Arg group. Oral lipid administration significantly increased plasma triglyceride levels in the L-NAME group and plasma triglyceride levels were significantly lower in the Arg group than in the Cont group. The area under the curve of plasma triglyceride levels after oral lipid administration was larger in the L-NAME group than in the Cont group. The administration of L-NAME increased insulin resistance and decreased lipid metabolism. L-arginine significantly increased urinary NO secretion but did not improve insulin resistance, although it did improve lipid metabolism. These findings suggest that supplementation of L-arginine cannot improve insulin resistance in diabetic rats probably due to increased insulin secretion by L-arginine.
D000818:Animals; D001120:Arginine / Q000008:administration & dosage*; D001835:Body Weight / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000178:diet therapy* / Q000378:metabolism; D019587:Dietary Supplements; D015309:Glucose Clamp Technique; D005951:Glucose Tolerance Test; D006973:Hypertension / Q000178:diet therapy* / Q000209:etiology / Q000378:metabolism; D007328:Insulin / Q000097:blood; D008297:Male; D024821:Metabolic Syndrome / Q000178:diet therapy* / Q000209:etiology / Q000378:metabolism; D019331:NG-Nitroarginine Methyl Ester / Q000008:administration & dosage; D009569:Nitric Oxide / Q000652:urine; D051381:Rats; D020334:Rats, Inbred OLETF; D020318:Rats, Long-Evans; D014280:Triglycerides / Q000097:blood
D007328:Insulin; D014280:Triglycerides; D009569:Nitric Oxide; D001120:Arginine; D019331:NG-Nitroarginine Methyl Ester